Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/39110
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchuler, M. H. H.-
dc.contributor.authorCUPPENS, Kristof-
dc.contributor.authorPloenes, T.-
dc.contributor.authorVanbockrijck, M.-
dc.contributor.authorWiesweg, M.-
dc.contributor.authorDarwiche, K.-
dc.contributor.authorSchramm, A.-
dc.contributor.authorMAES, Brigitte-
dc.contributor.authorHegedus, B.-
dc.contributor.authorSchildhaus, H-U.-
dc.contributor.authorHautzel, H.-
dc.contributor.authorTheegarten, D.-
dc.contributor.authorBaas, P.-
dc.contributor.authorHartemink, K.-
dc.contributor.authorDu Pont, B.-
dc.contributor.authorAigner, C.-
dc.date.accessioned2023-01-03T10:25:22Z-
dc.date.available2023-01-03T10:25:22Z-
dc.date.issued2022-
dc.date.submitted2022-12-23T13:49:52Z-
dc.identifier.citationANNALS OF ONCOLOGY, 33 (7) , p. S1404-
dc.identifier.urihttp://hdl.handle.net/1942/39110-
dc.description.abstractBackground: Preoperative immune checkpoint inhibitor therapy (PICIT) is a promising approach in curative treatment of non-small-cell lung cancer (NSCLC). This study explores the feasibility and efficacy of targeting PD-1 and LAG-3 prior to resection.-
dc.description.sponsorshipBristol Myers Squibb-
dc.language.isoen-
dc.publisherELSEVIER-
dc.titleA randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 09-13, 2022-
local.bibliographicCitation.conferencenameAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO)-
local.bibliographicCitation.conferenceplaceELECTR NETWORK-
dc.identifier.issue7-
dc.identifier.spageS1404-
dc.identifier.volume33-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrLBA37-
dc.identifier.doi10.1016/j.annonc.2022.08.034-
dc.identifier.isi000866211602444-
local.provider.typewosris-
local.description.affiliation[Schuler, M. H. H.; Wiesweg, M.; Schramm, A.] Univ Hosp Essen, Dept Med Oncol, Essen, Germany.-
local.description.affiliation[Cuppens, K.] Jessa Hosp, Dept Pulmonol & Thorac Oncol, Hasselt, Belgium.-
local.description.affiliation[Ploenes, T.; Theegarten, D.; Aigner, C.] Univ Med Essen, Ruhrlandklin, Dept Thorac Surg & Endoscopy, Essen, Germany.-
local.description.affiliation[Vanbockrijck, M.] Jessa Hosp, Dept Pathol, Hasselt, Belgium.-
local.description.affiliation[Darwiche, K.] Univ Med Essen, Ruhrlandklin, Dept Pulm Med, Essen, Germany.-
local.description.affiliation[Maes, B.] Jessa Hosp, Dept Lab Med, Hasselt, Belgium.-
local.description.affiliation[Hegedus, B.] Univ Med Essen, Ruhrlandklin, Dept Thorac Surg & Endoscopy, Essen, Germany.-
local.description.affiliation[Schildhaus, H-U.] Univ Hosp Essen, Inst Pathol, Essen, Germany.-
local.description.affiliation[Hautzel, H.] Univ Hosp Essen, Dept Nucl Med, Essen, Germany.-
local.description.affiliation[Baas, P.] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Lung Canc Ctr & Thorac Oncol, Amsterdam, Netherlands.-
local.description.affiliation[Hartemink, K.] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands.-
local.description.affiliation[Du Pont, B.] Jessa Hosp, Dept Thorac & Vasc Surg, Hasselt, Belgium.-
local.uhasselt.internationalyes-
item.accessRightsRestricted Access-
item.fullcitationSchuler, M. H. H.; CUPPENS, Kristof; Ploenes, T.; Vanbockrijck, M.; Wiesweg, M.; Darwiche, K.; Schramm, A.; MAES, Brigitte; Hegedus, B.; Schildhaus, H-U.; Hautzel, H.; Theegarten, D.; Baas, P.; Hartemink, K.; Du Pont, B. & Aigner, C. (2022) A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung). In: ANNALS OF ONCOLOGY, 33 (7) , p. S1404.-
item.fulltextWith Fulltext-
item.contributorSchuler, M. H. H.-
item.contributorCUPPENS, Kristof-
item.contributorPloenes, T.-
item.contributorVanbockrijck, M.-
item.contributorWiesweg, M.-
item.contributorDarwiche, K.-
item.contributorSchramm, A.-
item.contributorMAES, Brigitte-
item.contributorHegedus, B.-
item.contributorSchildhaus, H-U.-
item.contributorHautzel, H.-
item.contributorTheegarten, D.-
item.contributorBaas, P.-
item.contributorHartemink, K.-
item.contributorDu Pont, B.-
item.contributorAigner, C.-
crisitem.journal.issn0923-7534-
crisitem.journal.eissn1569-8041-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung).pdf
  Restricted Access		Published version85.97 kBAdobe PDFView/Open    Request a copy
Show simple item record

WEB OF SCIENCETM
Citations

8
checked on May 18, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.